Subcutaneous MG1113 in severe hemophilia A and B: phase 1b study for safety, pharmacokinetics, and pharmacodynamics
Research and Practice in Thrombosis and Haemostasis · 2026
DOI: 10.1016/j.rpth.2026.106910 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Research and Practice in Thrombosis and Haemostasis, 2026. Verfasst von Chur-Woo You und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Eulji University School of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Hemophilia A, Hemophilia B, Hemostatics. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
MG1113 is an immunoglobulin G4 monoclonal antibody targeting the Kunitz-2 domain of tissue factor pathway inhibitor (TFPI), developed as a hemostatic rebalancing agent for patients with hemophilia A or B.
Objectives
We aimed to investigate the safety, pharmacokinetics (PK), pharmacodynamics, and preliminary hemostatic effects of MG1113.
Methods
This phase 1b clinical trial was conducted in a multicenter, prospective, stepwise dose-escalating (2.0, 3.0, and 3.3 mg/kg) design. MG1113 was administered subcutaneously once weekly for 8 weeks.
Results
Fifteen male patients (n = 5/cohort) diagnosed with severe hemophilia A (n = 14) or B (n = 1) without inhibitors were enrolled. MG1113 was well tolerated, with an adverse event (AE) rate of 40.0% (6/15). No serious AEs, early withdrawals, or dose interruptions occurred. PK analysis demonstrated a nonlinear profile, with the peak plasma concentration at 33 to 48 hours post dose. Free TFPI and diluted prothrombin time (PT) decreased from baseline, while thrombin generation markers increased. Exploratory analysis showed a notable numerical reduction in annualized total bleeding rates at higher doses: 91.7% at 3.0 mg/kg and 76.2% at 3.3 mg/kg. The zero bleeding rate was 20.0%, 60.0%, and 40.0% at doses of 2.0, 3.0, and 3.3 mg/kg, respectively.
Conclusion
MG1113, administered subcutaneously as a prophylaxis in patients with severe hemophilia A or B without inhibitors for 8 weeks, demonstrated an acceptable safety profile with a PK profile suitable for once-a-week dosing. The pharmacodynamics marker changes were consistent with TFPI inhibition, which was associated with reductions in bleeding events.
Trial registration
This trial was prospectively registered at www.ClinicalTrials.gov (#NCT05493631).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Eulji University School of Medicine, Seoul, Republic of Korea.
- Department of Pediatrics, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Gwangju, Republic of Korea.
- Department of Pediatrics, Kyung Hee University Hospital at Gangdong, Seoul, Republic of Korea.
- Medical Division, GC Biopharma, Yongin, Republic of Korea.
- Department of Pediatrics, Daegu Catholic University School of Medicine, Daegu, Republic of Korea.
Zitieren
APA
You, C. W., Baek, H. J., Park, Y. S., Kim, B. R., Lee, H., Kim, S. H., Hwang, S. H., & Choi, E. J. (2026). Subcutaneous MG1113 in severe hemophilia A and B: phase 1b study for safety, pharmacokinetics, and pharmacodynamics. Research and Practice in Thrombosis and Haemostasis. https://doi.org/10.1016/j.rpth.2026.106910
Vancouver
You CW, Baek HJ, Park YS, Kim BR, Lee H, Kim SH, et al. Subcutaneous MG1113 in severe hemophilia A and B: phase 1b study for safety, pharmacokinetics, and pharmacodynamics. Research and Practice in Thrombosis and Haemostasis. 2026. doi:10.1016/j.rpth.2026.106910
BibTeX
@article{You2026,
author = {You, Chur-Woo and Baek, Hee Jo and Park, Young-Shil and Kim, Bo Ram and Lee, Hayoung and Kim, Seon Hui and Hwang, Sung Ho and Choi, Eun Jin},
title = {Subcutaneous MG1113 in severe hemophilia A and B: phase 1b study for safety, pharmacokinetics, and pharmacodynamics},
journal = {Research and Practice in Thrombosis and Haemostasis},
year = {2026},
doi = {10.1016/j.rpth.2026.106910}
}
EUVIMED